Figure 2
Figure 2. Combined pretreatment with KGF + PFT-β additively restores numbers of total and donor-derived, naive CD4+ and CD8+ T cells in LNs by 6 weeks after congenic BMT. Lethally irradiated B6 recipients of congenic (B6 Ly5.1+) BM were left untreated (BMT Control) or pretreated with KGF, PFT-β, or KGF + PFT-β and analyzed for the presence of T cells and Lti cells in the LNs at 6 weeks after BMT alongside unmanipulated age-/sex-matched B6 controls (non-BMT Control). Mean absolute numbers ± SEMs of (A) total CD4+CD3+ T cells; (B) total CD8+CD3+ T cells; (C) donor-derived, naive (CD62LhighCD44low) CD4+CD3+ T cells; (D) donor-derived, naive (CD62LhighCD44low) CD8+CD3+ T cells; and (E) donor-derived, CD4+CD3−CD11c−B220− Lti cells in the LNs are shown. LN node cells were pooled from inguinal, axillary, and mesenteric LNs. Data are representative of 3 experiments, each with 4 mice per group; *P < .05.

Combined pretreatment with KGF + PFT-β additively restores numbers of total and donor-derived, naive CD4+ and CD8+ T cells in LNs by 6 weeks after congenic BMT. Lethally irradiated B6 recipients of congenic (B6 Ly5.1+) BM were left untreated (BMT Control) or pretreated with KGF, PFT-β, or KGF + PFT-β and analyzed for the presence of T cells and Lti cells in the LNs at 6 weeks after BMT alongside unmanipulated age-/sex-matched B6 controls (non-BMT Control). Mean absolute numbers ± SEMs of (A) total CD4+CD3+ T cells; (B) total CD8+CD3+ T cells; (C) donor-derived, naive (CD62LhighCD44low) CD4+CD3+ T cells; (D) donor-derived, naive (CD62LhighCD44low) CD8+CD3+ T cells; and (E) donor-derived, CD4+CD3CD11cB220 Lti cells in the LNs are shown. LN node cells were pooled from inguinal, axillary, and mesenteric LNs. Data are representative of 3 experiments, each with 4 mice per group; *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal